Now Reading: Cohance Lifesciences shares rise despite weak first-quarter results
-
01
Cohance Lifesciences shares rise despite weak first-quarter results
Cohance Lifesciences shares rise despite weak first-quarter results
Shares in Cohance Lifesciences rose more than 2% even after the company reported a weak June quarter, with a net loss of Rs 24.1 crore against a year-earlier profit of Rs 48.9…
Shares in Cohance Lifesciences rose more than 2% even after the company reported a weak June quarter, with a net loss of Rs 24.1 crore against a year-earlier profit of Rs 48.9 crore, as revenue fell 23.1% to Rs 422 crore and EBITDA plunged 99% to Rs 1.2 crore, according to NDTV Profit. Investors appeared to focus on a US Food and Drug Administration inspection of the company's Pashamylaram plant in Hyderabad, which closed with a Form FDA 483 citing five observations, none related to data integrity, an outcome seen as reassuring given the stock's roughly 53% decline over the past year. Cohance said it is assessing the observations and will submit a corrective response within the prescribed timeline. The report does not specify what the five observations concern beyond confirming none involve data integrity.
Indian Opinion Analysis
The scale of the quarterly decline, a swing from profit to loss alongside a 99% collapse in EBITDA, is severe by any measure, which makes the market's muted reaction notable. The absence of data-integrity findings in this one inspection removes a specific, serious regulatory risk, but the five observations still need a corrective response, and the report does not say how significant they otherwise are. Investors may be pricing in relief rather than a turnaround, since the underlying business weakened sharply this quarter. Cohance's corrective response to the FDA observations, and its next quarterly results, will show whether this relief holds.
Source: www.ndtvprofit.com
This brief was synthesised by AI from the source linked above.
